COLUMN PLUS
Companies To Watch 14
Synthetic Biologics
Following a failed drug, a company
retrenches and reinvents itself.
FEATURE
The Art Of Optimizing Small
Biotech Market Caps 34
A Life Science Leader Editorial
Roundtable, Part One
INSIGHT
Antibiotic R&D;
Gains Traction 46
An Interview with Steven
Gilman, EVP & CSO of Cubist
Pharmaceuticals
Outsourcing Insights 16
Capitol Perspectives 10
European Guidelines 48
Bio Innovation Notes 20
Connect. Collaborate. Contribute.
APRIL 2014
Refusing
Play It Safe
at Merck Serono
President & CEO Belén Garijo
takes a risk-sharing approach
to developing people p. 24
to
0 4 1 4 _ C o v e r _ F . i n d d 1 0414_Cover_F.indd 1 3 / 2 4 / 2 0 1 4 1 : 3 7 : 0 9 P M 3/24/2014 1:37:09 PM